pentoxifylline has been researched along with Cardiac Diseases in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study shows that pentoxifylline has minimal temperature-dependent pharmacodynamic changes, and that it can inhibit elimination of both cAMP and cGMP at low temperatures." | 5.72 | Pharmacodynamic properties for inhibition of cAMP- and cGMP elimination by pentoxifylline remain unaltered in vitro during hypothermia. ( Dietrichs, ES; Fuskevåg, OM; Kondratiev, T; Kuzmiszyn, AK; Sager, G; Selli, AL; Smaglyukova, N, 2022) |
| "Cardiac cachexia was rapidly induced with monocrotaline in Sprague-Dawley rats." | 5.35 | Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia. ( Booth, FW; Lees, SJ; Steffen, BT, 2008) |
| "This study shows that pentoxifylline has minimal temperature-dependent pharmacodynamic changes, and that it can inhibit elimination of both cAMP and cGMP at low temperatures." | 1.72 | Pharmacodynamic properties for inhibition of cAMP- and cGMP elimination by pentoxifylline remain unaltered in vitro during hypothermia. ( Dietrichs, ES; Fuskevåg, OM; Kondratiev, T; Kuzmiszyn, AK; Sager, G; Selli, AL; Smaglyukova, N, 2022) |
| "Cardiac cachexia was rapidly induced with monocrotaline in Sprague-Dawley rats." | 1.35 | Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia. ( Booth, FW; Lees, SJ; Steffen, BT, 2008) |
| " Dose-response studies performed in anesthetized dogs showed that vintoperol 0." | 1.28 | Vasodilator and angioprotective activity of 1-ethyl-1-hydroxyalkyl-octahydroindolo[2,3a]quinolizine derivates. ( Kalaus, G; Kárpáti, E; Szabó, L; Szántay, C; Szombathelyi, Z, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Selli, AL | 2 |
| Kuzmiszyn, AK | 2 |
| Smaglyukova, N | 2 |
| Kondratiev, T | 2 |
| Fuskevåg, OM | 2 |
| Sager, G | 2 |
| Dietrichs, ES | 2 |
| Gholami, A | 1 |
| Ataei, S | 1 |
| Ahmadimoghaddam, D | 1 |
| Omidifar, N | 1 |
| Nili-Ahmadabadi, A | 1 |
| Vilar-Pereira, G | 1 |
| Resende Pereira, I | 1 |
| de Souza Ruivo, LA | 1 |
| Cruz Moreira, O | 1 |
| da Silva, AA | 1 |
| Britto, C | 1 |
| Lannes-Vieira, J | 1 |
| Steffen, BT | 1 |
| Lees, SJ | 1 |
| Booth, FW | 1 |
| Liu, H | 1 |
| Xiong, M | 1 |
| Xia, YF | 1 |
| Cui, NJ | 1 |
| Lu, RB | 1 |
| Deng, L | 1 |
| Lin, YH | 1 |
| Rong, TH | 1 |
| Dintenfass, L | 1 |
| Horton, JW | 1 |
| White, DJ | 1 |
| Hino, H | 1 |
| Shimizu, T | 1 |
| Konagai, N | 1 |
| Kudo, T | 1 |
| Szombathelyi, Z | 1 |
| Kárpáti, E | 1 |
| Kalaus, G | 1 |
| Szabó, L | 1 |
| Szántay, C | 1 |
1 review available for pentoxifylline and Cardiac Diseases
| Article | Year |
|---|---|
Action of drugs on the aggregation and deformability of red cells: effect of ABO blood groups.
Topics: ABO Blood-Group System; Alprenolol; Blood Coagulation; Blood Viscosity; Cell Adhesion; Erythrocyte A | 1983 |
8 other studies available for pentoxifylline and Cardiac Diseases
| Article | Year |
|---|---|
Pharmacodynamic properties for inhibition of cAMP- and cGMP elimination by pentoxifylline remain unaltered in vitro during hypothermia.
Topics: Cyclic AMP; Cyclic GMP; Heart Diseases; Humans; Hypothermia; Pentoxifylline | 2022 |
Pharmacodynamic properties for inhibition of cAMP- and cGMP elimination by pentoxifylline remain unaltered in vitro during hypothermia.
Topics: Cyclic AMP; Cyclic GMP; Heart Diseases; Humans; Hypothermia; Pentoxifylline | 2022 |
Pharmacodynamic properties for inhibition of cAMP- and cGMP elimination by pentoxifylline remain unaltered in vitro during hypothermia.
Topics: Cyclic AMP; Cyclic GMP; Heart Diseases; Humans; Hypothermia; Pentoxifylline | 2022 |
Pharmacodynamic properties for inhibition of cAMP- and cGMP elimination by pentoxifylline remain unaltered in vitro during hypothermia.
Topics: Cyclic AMP; Cyclic GMP; Heart Diseases; Humans; Hypothermia; Pentoxifylline | 2022 |
Pentoxifylline Attenuates Arsenic Trioxide-Induced Cardiac Oxidative Damage in Mice.
Topics: Animals; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Cardiotoxicity; Heart Diseases; Lipi | 2021 |
Combination Chemotherapy with Suboptimal Doses of Benznidazole and Pentoxifylline Sustains Partial Reversion of Experimental Chagas' Heart Disease.
Topics: Animals; Chagas Disease; Female; Flow Cytometry; Heart Diseases; Immunohistochemistry; Mice; Mice, I | 2016 |
Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia.
Topics: Animals; Anorexia; Blotting, Western; Body Weight; Cachexia; Eating; Enzyme-Linked Immunosorbent Ass | 2008 |
Studies on pentoxifylline and tocopherol combination for radiation-induced heart disease in rats.
Topics: Animals; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fibrosis; Heart; Heart Diseases; M | 2009 |
Free radical scavengers prevent intestinal ischemia-reperfusion-mediated cardiac dysfunction.
Topics: Animals; Catalase; Constriction; Free Radical Scavengers; Heart Diseases; Heart Rate; Intestines; Is | 1993 |
[Effectiveness of preoperative oral pentoxifylline treatment in cold blood cardioplegia].
Topics: Administration, Oral; Blood; Body Temperature; Cold Temperature; Heart Arrest, Induced; Heart Diseas | 1988 |
Vasodilator and angioprotective activity of 1-ethyl-1-hydroxyalkyl-octahydroindolo[2,3a]quinolizine derivates.
Topics: Animals; Dogs; Dose-Response Relationship, Drug; Female; Heart Diseases; Hemodynamics; Indoles; Male | 1991 |